Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

Table 1

Clinical characteristics of seven patients with CD 20 negative aggressive B-cell lymphoma.

	Age; (years)	Sex	WHO lymphoma subtype	HIV status	CD4 count; (/𝜇l)	Stage	LDH	IPI score	Primary therapy	Salvage therapy	Survival; (months)
(1)	49	M	Plasmablastic	+	250	IIE	Elevated	1	R-CHOP	n/a	36*
(2)	47	M	Plasmablastic	+	106	IVB	Elevated	3	R-CHOP	n/a	<1
(3)	37	M	Plasmablastic	+	45	IVA	Normal	1	CHOP	n/a	24*
(4)	33	M	Plasmablastic	+	84	IVB	Elevated	2	Hyper-CVAD	n/a	24*
(5)	42	M	Plasmablastic	+	47	IVA	Elevated	4	None	none	<1
(6)	44	M	BCL-U	−	n/a	IVB	Elevated	3	CHOP	Hyper-CVAD/ICE	6
(7)	40	F	BCL-U	−	n/a	IVB	Elevated	2	CHOP	DHAP	8

M: male, F: female, BCL-U: B cell lymphoma unclassifiable, n/a: not applicable, LDH: lactate dehydrogenase, IPI: international prognostic index, *still alive.